Artemether: Difference between revisions
| Line 5: | Line 5: | ||
==Overview== | ==Overview== | ||
'''Artemether''' ([[International Nonproprietary Name|INN]]) is an antimalarial for the treatment of multi-drug resistant strains of ''[[Plasmodium falciparum|falciparum]]'' [[malaria]]. Its combination (co-formulation) with [[Lumefantrine]] has first been marketed by [[Novartis]] under the brand names Riamet and Coartem. Today, this combination therapy is available as generic from several manufacturers. | |||
==Category== | ==Category== | ||
Revision as of 17:25, 6 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Overview
Artemether (INN) is an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria. Its combination (co-formulation) with Lumefantrine has first been marketed by Novartis under the brand names Riamet and Coartem. Today, this combination therapy is available as generic from several manufacturers.
Category
Antimalarial
US Brand Names
COARTEM®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | Compatibility, Reconstitution, and Stability | Directions For Use | How Supplied | Labels and Packages